KRAS and cancer: Furthermore, SET/CIP2A overexpression was frequently observed in cancers with mutations in various oncogenes (e.g., EGFR, KRAS, NRAS, and BRAF) (Fig. 8a, b and Supplementary Fig. 6a–d).